IgA nephropathy or Berger's disease is a primary glomerulonephritis characterized by mesangial deposits of IgA complexes. Over time, these deposits damage the kidney, causing 20% of adults with the disorder to progress to end stage renal disease (ESRD). Patients in ESRD require dialysis or a kidney transplant to survive. In the United States, approximately 800 patients per year develop ESRD caused by IgA nephropathy out of the 40,000 patients affected by the disorder.
BioMarin develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions. The company's product portfolio is comprised of two approved products and multiple clinical and preclinical product candidates. Approved products include Naglazyme(R) (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin, and Aldurazyme(R) (laronidase) for mucopolysaccharidosis I (MPS I), a product which BioMarin developed through a 50/50 joint venture with Genzyme Corporation. Investigational product candidates include Kuvan(TM) (sapropterin dihydrochloride), a Phase 3 product candidate for the treatment of phenylketonuria (PKU), and 6R-BH4 for cardiovascular indications, which is currently in Phase 2 clinical development for the treatment of peripheral arterial disease and sickle cell disease. For additional information, please visit http://www.BMRN.com. Information on BioMarin's website is not incorporated by reference into this press release. About IGAN Biosciences
IGAN Biosciences develops novel, safe biotherapeutics for diseases in
which current treatments are ineffective. The company's lead compound, a
protease designed f
|SOURCE BioMarin Pharmaceutical Inc.|
Copyright©2007 PR Newswire.
All rights reserved